ABSTRACT
Background Hepatitis B virus (HBV) remains endemic throughout sub-Saharan Africa despite the widespread availability of effective vaccines. We evaluated the feasibility of adding HBV testing and treatment of pregnant women and birth-dose vaccination of HBV-exposed infants to the HIV prevention of MTCT (PMTCT) program infrastructure in the Democratic Republic of the Congo (DRC), where HBV treatment and birth-dose vaccination programs are not established.
Methods As part of the HIV PMTCT program at two maternity centers in Kinshasa, DRC, pregnant women were screened for HBV at routine prenatal care registration. Pregnant women with high viral load and/or HBeAg positivity were offered tenofovir disoproxil fumarate (TDF). HBV-exposed infants received a birth-dose of HBV vaccine within 24 hours of life. The primary endpoint was the feasibility and acceptability of the study.
Findings Of 4,016 women screened, 109 (2.7%) were HBsAg-positive. Ten of 91 (11.1%) women evaluated had high-risk disease. Of 88 infants, 60 (68.2%) received a birth-dose vaccine; of these, 46 (76.7%) received a timely birth-dose. No cases of HBV MTCT were observed in our cohort. There were no serious adverse events associated with TDF nor with birth-dose vaccine. The study procedures were highly acceptable (>80%) among mothers.
Interpretation Adding HBV screening and treatment of pregnant women and infant birth-dose vaccination to existing HIV PMTCT platforms is feasible in countries like the DRC. Birth-dose vaccination against HBV integrated within the current Expanded Programme on Immunization (EPI) and HIV PMTCT program could accelerate progress toward HBV elimination in Africa.
- hepatitis B virus
- mother-to-child transmission
- birth-dose vaccination
- Democratic Republic of the Congo
Competing Interest Statement
GC is an employee and shareholder of Abbott Laboratories. PT received support from an ASTMH/Burroughs-Wellcome Fund award. JBP and PT report research support from Gilead Sciences; JBP also reports research support from the World Health Organization, and honoraria from Virology Education. All other authors report no potential conflicts.
Clinical Trial
NCT03567382
Funding Statement
This project was supported by a Gillings Innovation Laboratory award funded by the 2007 Gillings Gift to Gillings School of Global Public Health at UNC Chapel Hill. Abbott Laboratories provided HBV reagents free-of-charge for this study. The HIV PMTCT study whose infrastructure was leveraged for this project was supported by a grant from the National Institute of Health (NICHD R01HD087993). TFVdp testing was performed by the UNC Center for AIDS Research Clinical Pharmacology and Analytical Chemistry Core (P30AI050410). PT is supported by a grant from the National Institute of Health (NIAID K08AI148607). CEM received support from a grant from the National Institute of Health (NIGMS T32GM008719).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board approval was obtained from the University of North Carolina at Chapel Hill (#17-2090) and the Kinshasa School of Public Health (CE/ESP/001/2018) prior to initiation of the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-second authors.
Funding: This project was supported by a Gillings Innovation Laboratory award funded by the 2007 Gillings Gift to UNC-Chapel Hill’s Gillings School of Global Public Health. Existing infrastructure from an NIH R01HD087993 grant was leveraged for this project.
Data Availability
Datasets will not be made publicly available because they contain protected health information. However, the authors will share de-identified participant data, alongside the study protocol, statistical analysis plan and analytic code, upon reasonable request and with approval by an independent review committee..
Abbreviations
- ALT
- Alanine aminotransferase
- AST
- Aspartate aminotransferase
- DBS
- Dried Blood Spot
- DRC
- Democratic Republic of the Congo
- HBeAg
- Hepatitis B envelop Antigen
- HBsAg
- Hepatitis B surface Antigen
- HBV
- Hepatitis B Virus
- MTCT
- Mother-to-child Transmission
- PMTCT
- Prevention of Mother-to-child Transmission
- SSA
- Sub-Saharan Africa
- TDF
- Tenofovir Disoproxil Fumarate